Article
Multidisciplinary Sciences
Qing Guo, Shuai Shen, Gefei Guan, Chen Zhu, Cunyi Zou, Jingyuan Cao, Wen Cheng, Xiaoyan Xu, Juanhan Yu, Zhiguo Lin, Guoli Wang, Ling Chen, Peng Cheng, Anhua Wu
Summary: Glioblastoma (GBM) shares common signaling pathways involving TIM-3, an immune checkpoint, between tumor and non-tumor cells. The study reveals that TIM-3 in glioma cells not only regulates the malignant behaviors of glioma cells but also induces macrophage migration and transition to an anti-inflammatory/protumorigenic phenotype through the TIM-3/IL6 signal. Blocking this feedback loop may provide a novel therapeutic strategy for GBM.
Article
Oncology
Changlin Yang, Guimei Tian, Mariana Dajac, Andria Doty, Shu Wang, Ji-Hyun Lee, Maryam Rahman, Jianping Huang, Brent A. Reynolds, Matthew R. Sarkisian, Duane Mitchell, Loic P. Deleyrolle
Summary: This study reveals the diversity of cell types and dynamic behaviors in glioblastoma, particularly the heterogeneity between slow-cycling cells and cells defined by the expression of stem cell markers. The findings shed light on the potential mechanisms underlying tumor resilience and treatment resistance, and provide insights for the development of precision and effective therapies for brain cancer.
Article
Chemistry, Multidisciplinary
Yuanyan Wei, Qihang Chen, Sijing Huang, Yingchao Liu, Yinan Li, Yang Xing, Danfang Shi, Wenlong Xu, Weitao Liu, Zhi Ji, Bingrui Wu, Xiaoning Chen, Jianhai Jiang
Summary: This study reveals that the low expression of MAN1A1 in glioma stem cells (GSCs) results in the formation of high-mannose type N-glycan on CD133. The interaction between CD133 and DNMT1 through high-mannose type N-glycan activates p21 and p27, maintaining the slow-cycling state and promoting chemotherapy resistance and tumorigenesis in GSCs.
Article
Multidisciplinary Sciences
Ken Miyaguchi, Hongqiang Wang, Keith L. Black, Stephen L. Shiao, Rongfu Wang, John S. Yu
Summary: Efficient activation of T cells with tumor-associated antigens (TAAs) to glioblastoma (GBM) stem cells was achieved through the use of three different antigen sources loaded onto dendritic cells (DCs). An activated T cell (ATC) protocol was developed and optimized for a phase I clinical trial to target GSCs. The synthetic peptide pool loading method showed significantly increased cytotoxicity towards target cells.
SCIENTIFIC REPORTS
(2023)
Article
Neurosciences
Jiaxin Li, Fredrik Ek, Roger Olsson, Mattias Belting, Johan Bengzon
Summary: This study identified CD105(+) cells as a potential subset of glioma stem-like cells (GSCs) that play a crucial role in tumor growth and treatment resistance. CD105(+) cells exhibited stem-like characteristics and differentiated into osteocytes and adipocytes. They also produced immunosuppressive and protumorigenic cytokines. Targeting CD105(+) cells could reshape the tumor microenvironment and block glioblastoma progression.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2022)
Article
Biology
Yong Huang, Rut Tejero, Vivian K. Lee, Concetta Brusco, Theodore Hannah, Taylor B. Bertucci, Chrystian Junqueira Alves, Igor Katsyv, Michael Kluge, Ramsey Foty, Bin Zhang, Caroline C. Friedel, Guohao Dai, Hongyan Zou, Roland H. Friedel
Summary: The study demonstrates that glioblastoma cells elevate axon guidance molecule Plexin-B2 to increase invasiveness, and through modulating cellular biomechanics, Plexin-B2 promotes glioblastoma cell infiltration along axon fiber tracts in intracranial transplant models.
COMMUNICATIONS BIOLOGY
(2021)
Review
Cell Biology
Karina Biserova, Arvids Jakovlevs, Romans Uljanovs, Ilze Strumfa
Summary: Cancer stem cells, particularly in glioblastoma, play a crucial role in tumor resistance to treatment and recurrence. The regulatory mechanisms of glioma stem cells include tumor microenvironment, niche concept, metabolism, immunity, genetics, and epigenetics, which serve as potential targets for future treatments.Understanding the molecular markers and treatment resistance of GSCs in glioblastoma may lead to more effective therapeutic strategies in the future.
Article
Oncology
Tadas K. Rimkus, Austin B. Arrigo, Dongqin Zhu, Richard L. Carpenter, Sherona Sirkisoon, Daniel Doheny, Angelina T. Regua, Grace L. Wong, Sara Manore, Calvin Wagner, Hui-Kuan Lin, Guangxu Jin, Jimmy Ruiz, Michael Chan, Waldemar Debinski, Hui-Wen Lo
Summary: The study found that TUSC2 protein expression is reduced in glioblastoma compared to normal brain due to protein destabilization. NEDD4-mediated polyubiquitination is a novel mechanism for TUSC2 degradation in glioblastoma. TUSC2 loss promotes glioblastoma progression through upregulation of Bcl-xL and its knockout gene signature predicts poor patient survival.
Review
Biochemistry & Molecular Biology
David Eisenbarth, Y. Alan Wang
Summary: Glioblastoma (GBM) is a highly deadly and treatment-resistant cancer due to its heterogeneity at both cellular and microenvironmental levels. The recent advancements in sequencing technologies have revealed the diversity of cell states in GBM, which hampers accurate classification and effective treatments for the disease. Moreover, GBM heterogeneity is influenced by both intrinsic factors and differs between new and recurrent cases, as well as treatment-naive and experienced patients. Understanding and unraveling the complex cellular network underlying GBM heterogeneity is essential for developing new strategies to combat this deadly disease.
Review
Oncology
Moloud Sooreshjani, Shashwat Tripathi, Corey Dussold, Hinda Najem, John de Groot, Rimas V. Lukas, Amy B. Heimberger
Summary: Glioblastoma, a highly infiltrative tumor, often recurs despite multi-modal treatment. Novel strategies incorporating cytokines as potential therapeutic options, including virotherapy, systemic cytokine therapy, and cellular and gene therapy, are being explored to improve treatment outcomes in glioblastoma patients.
Review
Biochemistry & Molecular Biology
Jennifer K. Matsui, Haley K. Perlow, Alex R. Ritter, Rituraj Upadhyay, Raju R. Raval, Evan M. Thomas, Sasha J. Beyer, Clement Pillainayagam, Justin Goranovich, Shirley Ong, Pierre Giglio, Joshua D. Palmer
Summary: This review discusses the treatment modalities for glioblastoma, the mechanisms of radioresistance, and promising radiosensitizers. Small molecules and immunotherapy agents used in conjunction with radiotherapy have been studied in clinical trials. Recent preclinical studies regarding radiosensitizers for glioblastoma are also discussed.
Article
Engineering, Environmental
Xuefeng Zhang, Qing Guo, Zongren Zhao, Peng Cheng, Anhua Wu, Hongmei Liu
Summary: A new therapeutic strategy combining anticancer drugs and immunotherapy was developed to target tumor-associated macrophages and glioma stem cells, leading to inhibited tumor growth and prolonged survival in a mouse model of glioblastoma. These findings highlight the importance of this approach for the treatment of glioblastoma.
CHEMICAL ENGINEERING JOURNAL
(2023)
Article
Cell & Tissue Engineering
JongMyung Kim, Marine Potez, Chunhua She, Ping Huang, Qiulian Wu, Shideng Bao, Jeremy N. Rich, James K. C. Liu
Summary: Researchers have successfully isolated a 7-amino acid peptide, AWEFYFP, using in vitro and in vivo phage display biopanning methods. This peptide targets glioblastoma stem cells specifically and has the ability to penetrate the blood-brain barrier. It was found that Cadherin 2 is the receptor targeted by the peptide on glioblastoma cells.
Article
Oncology
Hannah Clancy, Michal Pruski, Bing Lang, Jared Ching, Colin D. McCaig
Summary: This study demonstrates opposing preferences for electric field responses in primary GBM differentiated cells and GSCs, which can be chemically inhibited by pioglitazone. Western blot analysis did not show any changes in PPARγ expression with or without exposure to the electric field.
EXPERIMENTAL CELL RESEARCH
(2021)
Article
Oncology
Sukanya Basu, Yang Dong, Rahul Kumar, Collene Jeter, Dean G. Tang
Summary: Cancer cell heterogeneity and plasticity pose significant challenges to effective clinical treatments. Research has shown that cancer cells can exhibit stem-like characteristics and undergo dynamic changes during tumor progression. In addition, tumors also contain a population of non-proliferative cells that are resistant to anti-mitotic drugs. Understanding these unique cell populations in tumors can lead to the development of new therapeutic strategies to prevent relapse and metastasis.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Neurosciences
Fabrice Arcizet, Koorosh Mirpour, Daniel J. Foster, Caroline J. Charpentier, James W. Bisley
JOURNAL OF NEUROPHYSIOLOGY
(2015)
Article
Multidisciplinary Sciences
Alan L. Jiao, Daniel J. Foster, Julia Dixon, Frank J. Slack
Article
Cell Biology
Daniel J. Foster, Hao-Ming Chang, Jeffrey R. Haswell, Richard I. Gregory, Frank J. Slack
Article
Multidisciplinary Sciences
Jeffrey R. Haswell, Kaia Mattioli, Chiara Gerhardinger, Philipp G. Maass, Daniel J. Foster, Paola Peinado, Xiaofeng Wang, Pedro P. Medina, John L. Rinn, Frank J. Slack
Summary: This study describes a method to modulate lncRNA expression during human embryonic stem cell differentiation and identifies key lncRNA loci involved in differentiation. A clustering approach was developed to infer mechanisms of action of lncRNA hits, leading to the validation of FOXD3-AS1 as a functional lncRNA essential for pluripotency and differentiation. The cell lines and methodology presented in this study can be adapted to discover and characterize novel regulators of differentiation into any lineage.
Article
Neurosciences
Fabrice Arcizet, Koorosh Mirpour, Daniel J. Foster, James W. Bisley